Khavinson Bioregulator Peptides: The Complete Guide to All 14 Compounds

Research-use content. This article is for informational purposes only and is not medical advice. Khavinson bioregulator peptides are not FDA-approved for any human indication.

Quick Answer

Khavinson bioregulator peptides are a class of very short peptides (2–4 amino acids) developed over four decades by Russian researcher Vladimir Khavinson. Unlike receptor-targeting peptides, they’re proposed to act inside the cell nucleus, on chromatin, to influence which genes a tissue expresses as it ages. Each compound in the lineup is associated with a specific organ or tissue system — pineal gland, thymus, cartilage, liver, and so on.

The supporting evidence comes almost entirely from Russian-institution research: some human cohort data, a larger body of rodent lifespan studies, and in vitro cell work. None of it has been independently replicated at the scale or standard Western regulators require, and no compound in the class has FDA approval for any US indication.

Who Was Vladimir Khavinson

Vladimir Khavinson is a Russian physician-researcher and the director of the St. Petersburg Institute of Bioregulation and Gerontology. Beginning in the 1970s, his group isolated and later synthesized short peptides from animal tissue extracts, organized around the idea that each organ produces its own tissue-specific regulatory peptides.

Over roughly 40 years, Khavinson’s program has generated a large publication record — commonly cited as approximately 775 papers and around 196 patents — along with several products registered as pharmaceuticals in Russia and a larger number sold internationally as supplements or research compounds. That output volume reflects one research program’s self-reported record, not independent verification by outside bodies, and it’s worth reading it that way.

The Theory: Bioregulators vs. Receptor-Targeting Peptides

Most peptides people are familiar with — semaglutide, BPC-157, and similar compounds — work the way hormones typically do: they bind a receptor on the outside of a cell, and that binding event triggers a signaling cascade inside the cell.

Khavinson’s bioregulators are proposed to work differently. Because they’re so short, the theory goes, they can cross the cell membrane and the nuclear membrane directly, then bind chromatin (the DNA-histone complex) and influence transcription — essentially nudging which genes an aging cell reads more or less of, without going through a surface receptor at all. This is sometimes described as an epigenetic mechanism rather than an endocrine one.

It’s a mechanistically distinct idea from GLP-1 agonism, and if you’re comparing peptide categories side by side, our guide to semaglutide, tirzepatide, and retatrutide covers the receptor-mediated side of that comparison in more detail.

It’s worth being direct about where this theory stands scientifically: the intranuclear, chromatin-binding mechanism is Khavinson’s own proposed model, described in his group’s publications and in vitro work. It has not been established as fact by independent structural or mechanistic studies outside that research program, and it remains a hypothesis rather than settled cell biology.

The Full Bioregulator Roster, by Tissue

Fourteen compounds make up the core lineup most vendors, including ours, carry. A structural note before the list: Khavinson’s group developed each target in two forms — a natural tissue-extract “Cytamin” or pharmaceutical complex, and a shorter synthetic peptide analog intended to reproduce the same effect. The synthetic short peptides are what’s typically sold as research compounds, and that’s the focus here.

Pineal gland / longevity — Epitalon (synthetic tetrapeptide Ala-Glu-Asp-Gly, modeled on the natural extract Epithalamin). The most studied compound in the class, with the most human cohort and rodent longevity data.

Immune system — Thymogen and Vilon. Thymogen is a dipeptide studied for general immune modulation; Vilon (also Lys-Glu) is one of the shortest bioregulators in the lineup, studied for similar immune-restoration effects and biological-age markers in rodent models.

Cartilage / joints — Cartalax (Ala-Glu-Asp), studied for cartilage and connective tissue support.

Respiratory system — Bronchogen (bronchial tissue) and Choluten (broader lung/respiratory tissue).

Cardiovascular system — Cardiogen (heart muscle) and Vesilute (vascular/circulatory tissue).

Liver — Livagen, studied for hepatic tissue support.

Digestive system — Ovagen, studied in connection with gastrointestinal tissue.

Pancreas / metabolic — Pancragen, studied in connection with pancreatic tissue.

Male reproductive / hormonal — Testagen, studied for testicular tissue function.

Prostate — Prostamax, studied for prostate tissue.

Brain / cognitive — Cortagen, studied for cerebral cortex function.

That’s the 13 SKUs stocked under our Bioregulators category, plus Epitalon, which we list separately under Anti-Aging & Longevity — a filing quirk rather than a scientific distinction; Epitalon is a bioregulator by mechanism and origin, it’s simply merchandised in the higher-traffic longevity category.

A few of these (Bronchogen, Cardiogen, Chonluten, Cortagen, Livagen, Prostamax, Vilon) are also available as nasal spray formulations alongside the standard lyophilized peptide vials — check each product page for format options.

If you’ve shopped around, you’ve probably noticed the same compound listed under different names on different sites. This isn’t a scam pattern so much as a byproduct of how Khavinson’s institute licensed and renamed compounds across different manufacturers and regions over 40 years. As two examples: what we sell as Testagen appears elsewhere as Testoluten; what we sell as Prostamax appears elsewhere as Libidon.

Same proposed target tissue, different commercial name, and in some cases subtly different formulations (natural extract vs. synthetic short peptide) get grouped under a shared marketing name by vendors who aren’t careful about the distinction. If you’re cross-referencing a compound between sites, check the amino acid sequence where it’s listed, not just the product name — that’s the only reliable way to confirm you’re looking at the same thing.

One naming question we haven’t resolved to our own satisfaction: some sources treat “Vesugen” and “Vesilute” as the same vascular-tissue compound under two names, others treat them as distinct. We currently stock Vesilute and are not linking to third-party Vesugen material until we can confirm whether they’re identical — worth knowing if you see both names used interchangeably elsewhere.

What the Evidence Shows

It’s more useful to tier the evidence by study type than to cite a raw publication count, because the count includes everything from large human cohorts down to fruit fly experiments.

Human cohort data. The most-cited human study is Khavinson and Morozov’s 2003 paper in Neuroendocrinology Letters (PMID 14523363), which followed 266 elderly subjects for 6–8 years. Reported mortality reductions ranged from roughly 1.6–2.1-fold for single-compound treatment (Thymalin or Epithalamin alone) up to about 4.1-fold in a subgroup that received combined Thymalin-plus-Epithalamin courses annually for six years.

That’s a substantial effect size if it holds up, but it’s one cohort, from one research group, published in a journal outside the mainstream gerontology literature, without an independent replication at Western RCT standards — no multi-site design, no blinded placebo arm reported at that scale, and no Phase 3-equivalent trial anywhere in the record since.

Rodent data. This is the largest and most consistent part of the evidence base. A 2010 review by Anisimov and Khavinson in Biogerontology, summarizing findings across the bioregulator class, reported lifespan extension in the general range of 20–40% across various rodent studies, alongside reduced spontaneous and chemically induced tumor rates in some models. Individual strain-specific results vary — spontaneously hypertensive rat (SHR) studies with Epitalon, for instance, have reported lifespan increases in the low double digits (around 12%) rather than the higher end of that range. Rodent lifespan-extension literature is a legitimate and fairly common category in aging research, but it’s also one where effect sizes routinely fail to translate to human outcomes, so it should be read as supportive rather than predictive.

In vitro data. Cell-culture work — including studies of Epitalon’s effect on telomerase activity in human somatic cell lines, and studies of multiple bioregulators’ effects on cytokine and proliferation markers in immune cell lines — makes up the mechanistic backbone of the theory. It’s useful for understanding a proposed pathway, but in vitro effects are the evidence tier furthest from clinical relevance, and they shouldn’t be read as evidence the compound does the same thing in a living organism.

Taken together: there’s a real, decades-long research program here, concentrated almost entirely within Russian institutions, with a plausible rodent evidence base, a thin and dated human evidence base, and essentially no independent Western replication at any stage. That’s a meaningfully different evidence profile than an FDA-approved drug or even a peptide with multiple international academic groups working on it, and it’s worth holding that distinction in mind regardless of which compound you’re reading about.

The Research Protocol: Pulsed Dosing

One thing that surprises people new to this category: Khavinson’s published protocols use short, pulsed courses rather than continuous daily use. In the studies, this generally took the form of roughly 10 consecutive days of a compound, repeated once or twice a year — often timed to spring and autumn — rather than an ongoing daily regimen. The stated rationale in Khavinson’s own writing is that a brief pulse is enough to shift gene expression patterns in the target tissue, and that continuous administration isn’t necessary or was not what produced the reported cohort results.

This is worth understanding as a description of how the studies were structured, not as usage instructions — the specific protocol that produced a given result in a specific paper doesn’t necessarily generalize to other compounds, doses, or populations, and none of it has been validated outside that research program. Anyone considering how a compound like this might be used should be working from the primary literature and, ideally, a conversation with a knowledgeable clinician, rather than a course-length figure lifted from a single 20-year-old paper.

Regulatory Status

No Khavinson bioregulator is FDA-approved for any indication in the United States. In Russia, a handful of these compounds are registered pharmaceuticals; in the US, they’re sold as research compounds, not as drugs, and product labeling reflects that.

Epitalon specifically has been part of a live regulatory process this year: in April 2026, it was removed from the FDA’s Category 2 list of bulk substances flagged for significant safety concerns, which cleared the way for review by the FDA’s Pharmacy Compounding Advisory Committee (PCAC). That review took place July 23–24, 2026, alongside six other peptides being considered for the 503A Bulks List — the list that governs which substances licensed compounding pharmacies can legally prepare.

FDA staff briefing documents ahead of the meeting recommended against adding Epitalon, along with the other six peptides under review, citing incomplete characterization data and insufficient human safety and effectiveness evidence for compounding purposes. PCAC recommendations are non-binding, and a final FDA decision on 503A inclusion typically follows months after a committee meeting, so this status may well have moved again by the time you’re reading this — check the FDA’s docket (FDA-2025-N-6895) directly for the current determination before relying on anything stated here.

To be clear about scope: 503A Bulks List inclusion is about whether compounding pharmacies can legally prepare a substance for individual prescriptions. It’s a separate question from full FDA drug approval, and neither outcome changes the research-compound status of Epitalon or any other bioregulator sold outside a compounding-pharmacy context.

Sourcing and Quality

Because none of these compounds are regulated as drugs, quality control is entirely a function of which manufacturer and vendor you’re buying from, not a baseline guaranteed by any agency. At minimum, look for:

A certificate of analysis (COA) matched to the specific batch you’re purchasing, not a generic COA reused across lots.
Third-party HPLC purity testing, with results in the 98–99%+ range disclosed rather than just claimed.
US-based manufacturing under documented quality processes, which at least gives you a domestic paper trail if something is wrong with a batch.

None of this converts a research compound into an approved medical product, but it’s the difference between a vendor you can hold accountable and one you can’t.

Choosing Where to Start

Because this class covers so many different tissue systems, the most useful framing isn’t “which one is best” but “which target tissue matches the area you’re actually researching.” A few common starting points, organized by the research question people tend to bring to this category:

General longevity / biological aging markers — Epitalon has the deepest and longest-running evidence trail in the class, including the only human cohort data, which is why it’s the compound most guides (including this one) lead with.
Immune system research — Thymogen and Vilon are the two most-studied immune-focused compounds, with Vilon’s dipeptide structure making it one of the simplest molecules in the lineup.
Joint and cartilage research — Cartalax is the dedicated compound for that tissue, with a comparatively thinner citation record than Epitalon or Vilon.
Cardiovascular or respiratory research — Cardiogen, Vesilute, Bronchogen, and Chonluten split that territory by more specific tissue (heart muscle vs. vasculature vs. bronchial vs. broader lung tissue), so the right one depends on which system you’re actually looking at.

Browse PrymaLab’s full catalog of USA-made research peptides alongside this bioregulator lineup if you’re comparing this class against receptor-mediated peptides.

Whichever compound you start with, read the primary literature for that specific compound rather than extrapolating from Epitalon’s evidence base — the human cohort data is specific to Thymalin and Epithalamin, and most of the other compounds in the lineup rest on a rodent and in vitro record only.

FAQ

What are Khavinson bioregulator peptides, in plain terms? They’re very short peptides, developed by Russian researcher Vladimir Khavinson, proposed to act on gene expression within a specific target tissue rather than through a surface receptor. Each compound in the lineup corresponds to a different organ system.

How is a bioregulator different from a receptor-targeting peptide like semaglutide or BPC-157? Receptor-targeting peptides bind a receptor on the outside of the cell and trigger a signaling cascade. Bioregulators are proposed to enter the cell nucleus directly and act on chromatin to influence gene transcription — a mechanistically distinct, and less established, pathway.

What does “10 days on, twice a year” mean, and why pulsed instead of continuous? It describes the protocol structure used in Khavinson’s published studies — short courses rather than daily ongoing use. The stated theory is that a brief pulse is sufficient to shift gene expression patterns; this is a description of past research design, not a validated usage recommendation for any given individual.

Is there real clinical evidence, or mostly animal data? There’s one significant human cohort study (266 subjects, published 2003) with substantial reported mortality reductions, but it hasn’t been independently replicated at a larger scale or Western RCT standard. The bulk of the evidence base — and the more consistent findings — come from rodent lifespan studies and in vitro cell work.

Are these FDA-approved or legal to buy in the US? No Khavinson bioregulator has FDA approval for any US indication. They’re sold as research compounds. Epitalon’s status within the FDA’s compounding-substance review process has been actively changing in 2026; check the FDA’s current docket before assuming any particular status.

Which bioregulator should someone start researching first? That depends on which tissue system is actually the subject of interest. Epitalon has the deepest evidence trail overall; compounds like Vilon, Cartalax, and Cardiogen are better matches if the research question is specifically immune, joint, or cardiac tissue rather than general aging markers.

Sources

Khavinson VK, Morozov VG. “Peptides of pineal gland and thymus prolong human life.” Neuroendocrinology Letters 2003;24(3-4):233–240. PMID 14523363.
Anisimov VN, Khavinson VK. “Peptide bioregulation of aging: results and prospects.” Biogerontology2010;11(2):139–149.
FDA Pharmacy Compounding Advisory Committee, meeting materials and briefing documents, July 23–24, 2026, Docket No. FDA-2025-N-6895.
Vladimir Khavinson biographical background (Wikipedia) — used for background only; all effectiveness and safety claims above are sourced to the primary literature and FDA materials cited.

Research-use content only. Nothing in this article constitutes medical advice, and none of the compounds discussed are FDA-approved for any human indication. Consult a qualified healthcare provider before making any decisions related to your health.